Hypoxia inducible factor network reflects kidney disease progression in diabetes and sodium-glucose co-transporters inhibition [0.03%]
缺氧诱导因子网络反映了糖尿病和钠-葡萄糖共转运抑制剂的肾脏疾病进展情况
Viji Nair,Akihiro Minakawa,Cathy Smith et al.
Viji Nair et al.
Hypoxia drives diabetic kidney disease (DKD) progression through Hypoxia Inducible Factor (HIF) signaling. The kidney's cellular heterogeneity and complex architecture pose challenges for directly assessing the pharmacologic effects on kidn...
Targeting ATP11B-YAP axis repairs mitochondrial function and inhibits neuronal ferroptosis to attenuate age-related cognitive decline [0.03%]
靶向ATP11B-YAP轴修复线粒体功能并抑制神经元铁死亡以缓解与年龄相关的认知衰退
Wenxin Qi,Qian Liu,Naijun Dong et al.
Wenxin Qi et al.
Brain aging is accompanied by cognitive decline and an increased risk of neurodegenerative disease, with neuronal aging being a key causative factor. Studies have shown that the earliest damage to blood-brain barrier (BBB) integrity occurs ...
The cost of cure: cancer therapies sculpt somatic evolution and signaling landscapes in normal tissues [0.03%]
治愈的代价：癌症疗法重塑正常组织的体细胞进化和信号景观
Yu-Jeong Jeong,In-Sung Song,Sung-Wuk Jang
Yu-Jeong Jeong
Luisa Chocarro,Leticia Fernández-Rubio,Karina Ausin et al.
Luisa Chocarro et al.
mTOR-driven integrin β4-enriched extracellular vesicles from lenvatinib-resistant hepatocellular carcinoma fuel lung metastasis via fibroblast-niche formation [0.03%]
仑伐替尼耐药肝细胞癌驱动的mTOR增殖、整合素β4富集型细胞外囊泡通过成纤维细胞巢促进肺转移
Tiantian Zou,Xufeng Wang,Haoting Sun et al.
Tiantian Zou et al.
Tumor-derived extracellular vesicles (EVs) play crucial roles in facilitating the colonization and growth of metastatic cancer cells in distant organs. Nevertheless, the precise mechanisms by which EVs contribute to therapy-resistant cancer...
Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance [0.03%]
抗膜 proximal AXL抗体重编程肿瘤微环境以克服免疫检查点抑制剂耐药性
Zuming Yang,Shuaishuai Cao,Jiaen Zhang et al.
Zuming Yang et al.
Immune-cold tumors fail to respond to immunotherapy due to insufficient lymphocyte infiltration within the tumor tissue. Increasing the objective response rate remains an urgent challenge. Here, we report the development of a monoclonal ant...
Shaosen Zhang,Yanrong Shen,Lingxuan Zhu et al.
Shaosen Zhang et al.
Esophageal cancer (EC), encompassing primarily esophageal squamous-cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), continues to pose a significant global health burden, which is largely due to delayed diagnosis and limited therap...
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial) [0.03%]
HDAC抑制剂涂地辛加小剂量卡培他滨联合内分泌治疗CDK4/6抑制剂治疗后进展的HR阳性HER2阴性晚期乳腺癌患者的临床疗效及探索性循环肿瘤细胞和ctDNA生物标志物分析：一项多中心II期研究（SYSUCC-020试验）
Huai-Liang Wu,Wen Xia,Zhengyang Xu et al.
Huai-Liang Wu et al.
Treatment options for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that progresses after CDK4/6 inhibitor (CDK4/6i) continue to evolve, and no single reg...
Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy [0.03%]
内质网应激与疾病发病机制及治疗的关系
Siyu Wei,Nan Zhang,Hao Zhang et al.
Siyu Wei et al.
Endoplasmic reticulum (ER) stress is a key cellular mechanism that is important in the development of many diseases, including cancer. Since the discovery of the unfolded protein response (UPR), research has greatly improved our understandi...
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer [0.03%]
STRATEGY-1：不可切除的RAS/BRAF野生型转移性结直肠癌患者的多队列、随机、开放标签的GERCOR-PRODIGE-39Ⅲ期临床试验
Benoist Chibaudel,Louis-Marie Dourthe,Thierry André et al.
Benoist Chibaudel et al.
Managing unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy, anti-angiogenic, and anti-epidermal growth factor receptor (EGFR) agents are available, strategy trials are needed to optimize ...